ClinicalTrials.Veeva

Menu

Effect of Lactoferrin in Pneumonia Treatment

A

Assiut University

Status

Not yet enrolling

Conditions

Pneumonia

Treatments

Drug: Pneumonia treatment
Drug: Lactoferrin

Study type

Interventional

Funder types

Other

Identifiers

NCT05431023
Pneumonia

Details and patient eligibility

About

Pneumonia is defind as the inflammation of lung tissue caused by an infectious agent that results in acute respiratory signs and symptoms. Community acquired pneumonia (CAP) is a major cause of morbidity and increased health care costs. In developing nations, pneumonia remains a significant cause of mortality in children.

Pneumonia occurs in 30 to 45 of every 1,000 children under 5 years of age; it is less common in 5- to 9-year olds (16 to 22/1,000) and in older children (7 to 16/1,000).

Streptococcus pneumoniae is the primary bacterial cause of pneumonia in infants and children. Viral etiologies become less prevalent and mycoplasmal and chlamydial infections become more prevalent with increasing age

Full description

Lactoferrin (LF) is iron-binding glycoprotein of the transferrin family that is expressed and secreted by glandular cells and is found in most body fluids . It appears at especially high concentrations in mammalian milk and was first identified in bovine milk , and was subsequently isolated from human milk.

LFs bacteriostatic function is due to its ability to take up the Fe3+ ion, limiting use of this nutrient by bacteria at the infection site and inhibiting the growth of these microorganisms as well as the expression of their virulence factors .

Enrollment

72 estimated patients

Sex

All

Ages

1 month to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Pneumonia patients
  • from the age of one month to the age of 18 years .

Exclusion criteria

Neonates and any children with :

  • immune deficiency
  • congenital heart disease
  • neuromascular disorder
  • genetic syndromes

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

72 participants in 2 patient groups

Patients with pneumonia who receive only treatment for pneumonia
Experimental group
Description:
They receive only treatment for pneumonia
Treatment:
Drug: Pneumonia treatment
pneumonia patients receive treatment for pneumonia and lactoferrin
Experimental group
Description:
They receive treatment for pneumonia and lactoferrin
Treatment:
Drug: Pneumonia treatment
Drug: Lactoferrin

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems